Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen

References

• NorelliMCasucciMBoniniCBondanzaAClinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effectsBiochim Biophys Acta2016186519010026748354
   PubMed Web of Science ®Google Scholar
• JuneCHAdoptive T cell therapy for cancer in the clinicJ Clin Invest200711761466147617549249
   PubMed Web of Science ®Google Scholar
• PaluckaKBanchereauJCancer immunotherapy via dendritic cellsNat Rev Cancer201212426527722437871
   PubMed Web of Science ®Google Scholar
• LeeSCSrivastavaRMLopez-AlbaiteroAFerroneSFerrisRLNatural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunityImmunol Res2011502–324825421717064
   PubMed Web of Science ®Google Scholar
• GarridoFAlgarraIGarcia-LoraAMThe escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesionsCancer Immunol Immunother201059101601160620625726
   PubMed Web of Science ®Google Scholar
• CampoliMFerroneSHLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene200827455869588518836468
   PubMed Web of Science ®Google Scholar
• MarincolaFMJaffeeEMHicklinDJFerroneSEscape of human solid tumors from T-cell recognition: molecular mechanisms and functional significanceAdv Immunol20007418127310605607
   PubMedGoogle Scholar
• ChmielewskiMHombachAAAbkenHAntigen-specific T-Cell activation independently of the MHC: chimeric antigen receptor-redirected T CellsFront Immunol2013437124273543
   PubMed Web of Science ®Google Scholar
• SadelainMRiviereIBrentjensRTargeting tumours with genetically enhanced T lymphocytesNat Rev Cancer200331354512509765
   PubMed Web of Science ®Google Scholar
• GuestRDHawkinsREKirillovaNThe role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigensJ Immunother200528320321115838376
   PubMed Web of Science ®Google Scholar
• HeuserCHombachALoschCManistaKAbkenHT-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cellsGene Ther200310171408141912900755
   PubMedGoogle Scholar
• LamersCHGratamaJWPouwNMParallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expressionHum Gene Ther200516121452146216390276
   PubMed Web of Science ®Google Scholar
• WangJJensenMLinYOptimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domainsHum Gene Ther200718871272517685852
   PubMed Web of Science ®Google Scholar
• GyobuHTsujiTSuzukiYGeneration and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptorCancer Res20046441490149514973062
   PubMedGoogle Scholar
• BarberAZhangTDeMarsLRConejo-GarciaJRobyKFSentmanCLChimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancerCancer Res200767105003500817510432
   PubMed Web of Science ®Google Scholar
• ZhangTLemoiBASentmanCLChimeric NK-receptor-bearing T cells mediate antitumor immunotherapyBlood200510651544155115890688
   PubMed Web of Science ®Google Scholar
• GlienkeWEsserRPriesnerCAdvantages and applications of CAR-expressing natural killer cellsFront Pharmacol201562125729364
   PubMed Web of Science ®Google Scholar
• ChuJDengYBensonDMCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaLeukemia201328491792724067492
   PubMed Web of Science ®Google Scholar
• AltvaterBLandmeierSPschererS2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cellsClin Cancer Res200915154857486619638467
   PubMed Web of Science ®Google Scholar
• RedmondWLLinchSNKasiewiczMJCombined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunityCancer Immunol Res20142214215324778278
   PubMed Web of Science ®Google Scholar
• MeleroIHervas-StubbsSGlennieMPardollDMChenLImmunostimulatory monoclonal antibodies for cancer therapyNat Rev Cancer2007729510617251916
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• ArakawaFShibaguchiHXuZKurokiMTargeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activityAnticancer Res2002226C4285428912553071
   PubMedGoogle Scholar
• HuangJShibaguchiHZhaoJIgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activityAnticancer Res2006262A1057106316619506
   PubMedGoogle Scholar
• ImakiireTKurokiMShibaguchiHGeneration, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigenInt J Cancer2004108456457014696121
   PubMedGoogle Scholar
• ShibaguchiHLuoNXKurokiMA fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cellsAnticancer Res2006266A4067407217195459
   PubMedGoogle Scholar
• ShibaguchiHTsuruHKurokiMEnhancement of the antitumor effect on combination therapy of an anticancer drug and its antibody against carcinoembryonic antigenChemotherapy201258211011722507917
   PubMedGoogle Scholar
• ShirasuNShibaguciHKurokiMYamadaHConstruction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigenAnticancer Res20103072731273820683006
   PubMedGoogle Scholar
• ZhaoJKurokiMShibaguchiHRecombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cellsOncol Res200817521722218980018
   PubMedGoogle Scholar
• SrivastavaRMLeeSCAndrade FilhoPACetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patientsClin Cancer Res20131971858187223444227
   PubMed Web of Science ®Google Scholar
• MatsumotoHLiaoSArakawaFTargeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibodyAnticancer Res20022242001200712174877
   PubMedGoogle Scholar
• GernerMYHeltemes-HarrisLMFifeBTMescherMFCutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor controlJ Immunol201319131011101523804712
   PubMedGoogle Scholar
• YuPBamfordRNWaldmannTAIL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cellsEur J Immunol201444113330334125142300
   PubMedGoogle Scholar
• CecilDLHoltGEParkKHElimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activityCancer Res201474102710271824778415
   PubMedGoogle Scholar
• AlvarezMBouchlakaMNSckiselGDSungurCMChenMMurphyWJIncreased antitumor effects using IL-2 with anti-TGF-beta reveals competition between mouse NK and CD8 T cellsJ Immunol201419341709171625000978
   PubMedGoogle Scholar
• KermerVHornigNHarderMBondarievaAKontermannREMullerDCombining antibody-directed presentation of IL-15 and 4–1BBL in a trifunctional fusion protein for cancer immunotherapyMol Cancer Ther201313111212124198185
   PubMedGoogle Scholar